Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
J Allergy Clin Immunol Pract. 2022 Aug;10(8):2154-2162. doi: 10.1016/j.jaip.2022.04.033. Epub 2022 May 6.
Aquagenic urticaria (AquaU) is a rare variant of chronic inducible urticaria where wheals occur after skin contact with water. Information on clinical manifestations and treatment outcomes is limited, which makes the management of AquaU challenging.
To systematically review disease features and relevant triggers of AquaU and patients' response to treatment.
Related articles were searched by use of the terms "aquagenic urticaria" and "aquagenic angioedema" until June 2021 and reviewed according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis recommendations.
A total of 77 patients with AquaU were investigated in 59 studies including 47 case reports and 12 case series. AquaU predominantly presented in women (47 patients, 61%), and the mean age of onset of the disease was 19.6 ± 10.8 years (range: 0-54 years). Wheals commonly occurred in localized areas and regardless of the water temperature. Based on the reviewed evidence, AquaU can be classified as familial AquaU (FAquaU, 18.2%) and acquired AquaU (AAquaU, 81.8%). Although many treatments were used in both subtypes of AquaU, the use of second-generation H antihistamines (2AH) was reported most often to achieve marked improvement in both subtypes. The use of topical therapies in AquaU, which most commonly use hydrophobic vehicles, is poorly documented and of controversial efficiency.
AquaU is proposed to be classified into 2 subtypes, FAquaU and the more common AAquaU. Treatment with a 2AH is recommended as the first-line treatment for both types of AquaU. Further studies are required to fill knowledge gaps.
水致荨麻疹(AquaU)是一种罕见的慢性诱导性荨麻疹变异,其特征为皮肤接触水后出现风团。目前关于该病临床表现和治疗效果的信息有限,这使得 AquaU 的管理颇具挑战性。
系统回顾 AquaU 的疾病特征和相关触发因素,以及患者对治疗的反应。
使用“aquagenic urticaria”和“aquagenic angioedema”等术语搜索相关文章,检索截至 2021 年 6 月,并根据系统评价和荟萃分析报告的首选条目进行综述。
共纳入 59 项研究的 77 例 AquaU 患者,包括 47 例病例报告和 12 例病例系列研究。AquaU 主要发生于女性(47 例,61%),疾病发病的平均年龄为 19.6±10.8 岁(范围:0-54 岁)。风团常出现在局部区域,与水温无关。根据已审查的证据,AquaU 可分为家族性 AquaU(FAquaU,18.2%)和获得性 AquaU(AAquaU,81.8%)。尽管在这两种亚型的 AquaU 中都使用了多种治疗方法,但报告最多的是第二代 H1 抗组胺药(2AH),两种亚型的改善均显著。AquaU 中使用的局部治疗方法(最常使用疏水性载体)的文献记载较差,且其疗效存在争议。
建议将 AquaU 分为 2 种亚型,即 FAquaU 和更常见的 AAquaU。推荐使用 2AH 作为两种类型的 AquaU 的一线治疗药物。需要进一步研究以填补知识空白。